Advertisement
Mr. Rosa brings over 20 years of human resources experience to theCompany. Most recently, Mr. Rosa worked at Carl Zeiss Meditec, Inc. as VicePresident of Worldwide Human Resources, a position he had held since May of2002. He was an integral part of the senior management team overseeing thecompany's growth and the commercial launch of several ophthalmology andsurgical microscopy devices. Prior to Carl Zeiss, Mr. Rosa served as VicePresident, Human Resources at COR Therapeutics, Inc., building the developmentand commercial organizations and launching Integrilin(R) in the cardiovascularangioplasty market. Before joining COR, Mr. Rosa held senior human resourcesand key administrative management positions with ReplayTV, Inc., GenelabsTechnologies, Inc., and Sony Electronics Inc. Prior to 1990, Mr. Rosa heldsimilar management positions with the General Electric Company where hestarted his career in human resources.
Advertisement
"I'm pleased to have Marco join our management team and help to developthe future of the company as we continue our late-stage product developmentand move toward potential commercialization," said Timothy S. Nelson,President and Chief Executive Officer of MAP Pharmaceuticals. "Marco bringsunique company building expertise to our efforts to develop improved therapiesfor children and adults who suffer from diseases that we believe are notadequately treated by currently available medicines."
In addition to his extensive human resources experience, Mr. Rosa servedas a Captain in the BioMedical Corps of the United States Air Force. Mr. Rosareceived his B.A. degree in Psychology from St. Michael's College and his M.A.degree in Counseling Psychology from New York University.
About MAP Pharmaceuticals, Inc.
MAP Pharmaceuticals develops and plans to commercialize new therapies forchildren and adults who suffer from chronic conditions that it believes arenot adequately treated by currently available medicines. The Company appliesits proprietary inhalation technologies to enhance the therapeutic benefitsand commercial attractiveness of proven drugs while minimizing risk bycapitalizing on their known safety, efficacy and commercialization history.MAP Pharmaceuticals has two drug candidates, Unit Dose Budesonide and MAP0004,in late stage development for the potential treatment of pediatric asthma andmigraine respectively. MAP Pharmaceuticals' pipeline also includes a drugcandidate in early clinical development for the treatment of asthma andchronic obstructive pulmonary disease.
Additional information about MAP Pharmaceuticals can be found athttp://www.mappharma.com.
SOURCE MAP Pharmaceuticals, Inc.
